The Nasdaq Biotechnology index also was sinking 0.8%.
In company news, CureVac (CVAC) slid over 14% after BofA Securities lowered its rating for the early-stage biopharmaceuticals company to underperform from neutral and also slashed its price target for CureVac shares to $20 apiece.
Applied DNA Sciences (APDN) was sinking 7.2% this afternoon, reversing an 8.7% mid-morning advance that followed the company Friday asking the US Food and Drug Administration for an emergency use authorization for its Linea 2.0 reverse transcription-polymerase chain reaction assay and at-home sample collection kit for the virus causing COVID-19. Samples are mailed to Applied DNA's clinical labs unit, with results available in 24 to 48 hours.
Medtronic (MDT) was little changed, paring a more than 1% decline earlier Friday that followed the FDA issuing a Class 1 recall - the agency's most serious type of recall - for the company's HawkOne atherectomy system due to risk of damage and serious events the device used to remove plaque from arteries can cause, including arterial rupture. The FDA has received 163 HawkOne complaints, including 55 reports of injuries.
|MKM Partners Starts Dorman Products at Buy With $129...|
|Canaan Posts Higher Q1 Earnings, Revenue; Provides Q...|
|Stifel Downgrades Target Corp. to Hold From Buy, Adj...|
|Piper Sandler Adjusts AlloVir's Price Target to $34 ...|
|NuScale Power, Associated Electric Cooperative Sign ...|